August 19, 2020
August 19, 2020 – The U.S. FDA has approved an expanded indication for Xeomin® (incobotulinumtoxinA)
intramuscular or intraglandular injection, manufactured by Merz Pharmaceuticals.
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
Global Reach Health
August 17, 2020
August 17, 2020 – The U.S. FDA has approved EnspryngTM (satralizumab-mwge), manufactured by
Genentech, to treat neuromyelitis optica spectrum disorder (NMOSD) in adult
August 12, 2020
August 12, 2020 – The U.S. FDA has approved ViltepsoTM (viltolarsen), manufactured by NS Pharma, to
treat Duchenne muscular dystrophy (DMD) in patients who have
August 10, 2020
August 10, 2020 – The U.S. FDA has approved OlinvykTM (oliceridine) injection, manufactured by Trevena,
for use in adults for whom alternative treatments are inadequate to manage
August 7, 2020
August 7, 2020 – The U.S. FDA has approved Lampit® (nifurtimox), manufactured by Bayer, to treat
pediatric patients who weigh at least 2.5kg (5.5 pounds) and
August 7, 2020
August 7, 2020 – The U.S. FDA has approved EvrysdiTM (risdiplam), manufactured by Genentech, to treat spinal muscular atrophy (SMA) in patients who are at least two months old.
August 6, 2020
August 6, 2020 – The U.S. FDA has approved BlenrepTM (belantamab mafodotin-blmf), manufactured by
GlaxoSmithKline, for use as a single agent to treat adults who have
August 6, 2020
August 6, 2020 – The U.S. FDA has approved an expanded indication for Dovato® (dolutegravir/
lamivudine) oral tablets, manufactured by ViiV Healthcare. The drug is